scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
46 hedge funds and large institutions have $114M invested in scPharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 5 closing their positions.
27% more capital invested
Capital invested by funds: $89.6M → $114M (+$24.4M)
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
0.67% more ownership
Funds ownership: 62.02% → 62.69% (+0.67%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 47 → 46 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$4.18M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.49M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$1.36M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$787K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$704K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$5.4M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.08M |
| 3 |
Renaissance Technologies
New York
|
-$382K |
| 4 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
-$204K |
| 5 |
VF
Virtu Financial
New York
|
-$192K |
SCPH Hedge Fund Activity: Q1 2021 in Review
46 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q1 2021, worth a combined $114M — up 27% from $89.6M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SCPH and 4 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 17 added.
The largest buyer was Goldman Sachs, adding an estimated $4.18M. The largest seller was RA Capital Management, cutting an estimated $5.4M.
- 46 institutional investors held scPharmaceuticals (SCPH) as of Q1 2021, down from 47 in Q4 2020.
- Funds reported $114M of scPharmaceuticals stock for Q1 2021, up 27% quarter-over-quarter.
- 4 funds opened new scPharmaceuticals positions in Q1 2021 and 5 closed out, a net change of -1 holder.
- The largest scPharmaceuticals buyer in Q1 2021 was Goldman Sachs, an estimated $4.18M added.
- The largest scPharmaceuticals seller in Q1 2021 was RA Capital Management, an estimated $5.4M sold.
Based on aggregated 13F filings for Q1 2021.